by Leah King, PharmD, JD, Independent Pharmacy Consultant & Charlotte Chovanec, RN, BSN, MHA, Clinical Director Although we don’t hear as much about it as we once did, the opioid crisis has continued to rage during the COVID-19 pandemic. Originally issued in October 2020, and updated in April 2021, the American Medical Association (AMA) published […] Continue
So far, 2021 has differed from previous years in many respects, but one thing has held true – drug prices went up. In late December and early January, drug manufacturers increased the price of more than 700 drugs. On average, prices rose by 4.5%.[1] Both of these numbers are consistent with price increases over the […] Continue
For the past several months, you likely haven’t read or seen much about the opioid crisis. All of the information about the opioid crisis that once flooded your inboxes and social media feeds has seemingly been replaced with news related to the COVID-19 pandemic. While it can sometimes be said that no news is good […] Continue
On July 16th, the FDA approved Orphengesic Forte, a non-opioid combination analgesic for the treatment of mild to moderate pain associated with acute musculoskeletal conditions. The FDA’s approval came earlier than expected, which many have viewed as a reinforcement of the FDA’s commitment to do everything in its power to combat the opioid epidemic. Orphengesic […] Continue
Patients with chronic pain often present a challenging treatment scenario for health care practitioners. This has historically been the case, and the opioid crisis has served to create additional challenges by discouraging the use of opioids which have traditionally been the mainstays of pain therapy. Because of the opioid epidemic, treatment guidelines have emerged which […] Continue